Portfolio Expansion Orphalan's acquisition of Orphelia Pharma expands its rare pediatric neurology and oncology portfolio, complementing existing Cuvrior products and creating opportunities for co-development, co-promotion, and geographic expansion in orphan-disease markets.

Access Partnerships Active partnerships with MAP International and the Wilson Disease Association enable NGO-driven access for Cuvrior in developing countries, providing a blueprint for scalable patient access programs and regional distribution for additional assets.

Orphan Leadership A focused strategy on Wilson disease and other orphan indications positions Orphalan to engage neurology clinics, pediatric hospitals, and disease-specific patient groups, supporting rapid adoption and potential cross-sell of Orphelia assets.

Data Driven Growth A data‑driven approach leveraging Python and other tools supports market analytics, regulatory submissions, and payer evidence generation to inform pricing, access strategies, and expansion plans.

Scale Ready Ops With US/EU launches and a mid‑sized global footprint, Orphalan can exploit manufacturing, supply chain, and distribution capabilities to enter new regions and pursue licensing or contract‑manufacturing partnerships for scaled growth.